Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • LP.8.1

    - PMLiVE

    Roche’s Lunsumio receives positive CHMP opinion for follicular lymphoma

    The recommendation for the subcutaneous formulation follows encouraging trial data

    - PMLiVE

    Invivyd working with FDA towards potential Biologics License Application for COVID-19

    The company plans head-to-head safety evaluation with COVID-19 vaccine, pending regulatory alignment

    - PMLiVE

    FDA approves Pfizer and BioNTech’s jab for COVID-19

    Globally, five billion doses of the companies’ vaccine have been distributed

    EU flag

    CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication

    Non-small cell lung cancer accounts for up to 90% of all lung cancer cases

    - PMLiVE

    Eli Lilly’s Alzheimer’s disease drug donanemab recommended by CHMP

    Up to 6.9 million people in Europe are affected by the neurodegenerative disorder

    - PMLiVE

    Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP

    Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1

    - PMLiVE

    Moderna shares positive phase 3 results for mRNA flu vaccine candidate

    More than 600,000 people in the US were hospitalised due to flu-related illness last year

    EU flag

    CHMP recommends tablet formulation of BeOne’s targeted cancer drug Brukinsa

    The new formulation would allow blood cancer patients to halve their daily pill intake

    - PMLiVE

    Sanofi’s Sarclisa recommended by CHMP for new multiple myeloma indication

    Around 46,000 cases of the disease are expected to be diagnosed in Europe this year

    - PMLiVE

    Ipsen receives CHMP recommendation for Cabometyx in neuroendocrine tumours

    The number of patients newly diagnosed with NETs is believed to be on the rise

    - PMLiVE

    Moderna’s RSV vaccine mRESVIA granted FDA approval to protect younger adults

    The vaccine is already approved in the US for use in adults aged 60 years and older

    - PMLiVE

    AstraZeneca receives CHMP recommendation for Imfinzi regimen in bladder cancer

    More than 614,000 cases of bladder cancer are diagnosed globally every year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links